StreetAlpha.app
Home › Stocks › CRDF

Cardiff Oncology, Inc. (CRDF)

$0.85
▼ −0.15%
LAST CLOSE · NOV 17

Cardiff Oncology is a San Diego biotechnology company developing onvansertib, an oral drug for several cancers. It last closed at $0.85 on Nov 17, down 0.15% on the day. The average 12-month price target from 2 analysts is $8.50 (+904.3% from the last close), with a high of $9.00 and a low of $8.00.

AI Auto Pilots
Is CRDF in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$559K
+11.6% vs a year ago
Net income
−$37.6M
−6735.2% margin
EPS (diluted)
−$0.54
Free cash flow
−$39.9M
−7145.3% margin
Valuation
Market cap
$65.8M
77.8M shares
P/E
–
No P/E while losing money
Price to sales
117.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$12.1M
At Sep 30
Shareholder equity
$28.1M
Shares outstanding
77.8M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $359K$359KFY2021FY2022: $386K$386KFY2022FY2023: $488K$488KFY2023FY2024: $683K$683KFY2024FY2025: $593K$593KFY2025

From CRDF's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CRDF in the past 90 days, not enough for a consensus
Average 12-month target
$8.50
▲ 904.3% upside

Based on 2 analysts who set a price target on CRDF in the past 90 days. The average target is $8.50, with a high of $9.00 and a low of $8.00, compared with the last close of $0.85.

Low $8.00Avg $8.50High $9.00
Blue marker: last close $0.85
Highest target$9.00
Average target$8.50
Lowest target$8.00
Latest rating changes
Craig-HallumInitiated
Sep 25Buy$2 → $8
HC Wainwright & Co.Upgrade
Sep 15Buy$9
Craig-HallumDowngrade
Jun 3Hold$2
DateFirmActionRatingPrice target
Sep 25Craig-HallumInitiatedBuy$2 → $8
Sep 15HC Wainwright & Co.UpgradeBuy$9
Jun 3Craig-HallumDowngradeHold$2
Loading…

Technical Analysis

CRDF · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 58% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $0.84, and the nearest resistance the Pivot at $0.85.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.3%/day
Key levels
$3.3152 week high+289.4%
$1.34200 day average+57.6%
$1.0350 day average+21.2%
$1.02100 day average+20.0%
$0.95Swing high (Oct 28)+11.8%
$0.91Pivot R1+7.1%
$0.85Pivot+0.0%
$0.85Last close
$0.8420 day average−1.2%
$0.79Pivot S1−7.1%
$0.78Swing low (Oct 27)−8.2%
$0.7152 week low−16.5%
Indicators
RSI (14)46.53Middle of its rangeNeutral
MACD-0.06Above its signal lineBullish
Stochastic40.1Middle of its rangeNeutral
ADX (14)31.3Trending up
Williams %R-43.3Oversold below −80, overbought above −20Neutral
CCI (20)4.1Oversold below −100, overbought above 100Neutral
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 9.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRDF

What happened before

See how CRDF did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CRDF usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CRDF has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CRDF in the last 90 days.

Loading…

See today’s whale options flow across the market →

CRDF Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼19 buying vs 58 selling
  • ▼Held by funds -0.8 pts
  • ▼Funds holding -28
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding76104−26.9%
In funds' top 1010–
Held by funds23.4%24.2%−0.8 pts
New / increased3 / 1620 / 34−64.8%
Reduced / sold out28 / 3026 / 31+1.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRDF institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRDF is in one of them and how their past CRDF trades turned out.

CRDF in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRDF in an article yet. Here's the latest on the wider market.

About Cardiff Oncology

Cardiff Oncology is a biotechnology company based in San Diego, California, that develops cancer treatments. Its lead candidate, onvansertib, is an oral drug designed to block the PLK1 enzyme, and it is tested alone and alongside standard cancer therapies. The company is running studies in colorectal, pancreatic, lung, breast and blood cancers, focusing on patients whose tumors carry certain genetic markers.

Headquarters
San Diego, CA